Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）
Ontology highlight
ABSTRACT:
DISEASE(S): Rectal Neoplasms,Colorectal Cancer,Locally Advanced Rectal Cancer
PROVIDER: 13467 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Roseburia sensitizes colorectal cancer to radiotherapy
| PRJEB45422 | ENA
Project description:oral microbiota and radiotherapy for CRC
| PRJEB38064 | ENA
Project description:The recruitment of monocytes and their differentiation into immunosuppressive cells is associated with the negative outcome of non-conformal radiotherapy (RT). However, non-conformal RT is irrelevant in the clinic, and little is known about the role of monocytes following radiotherapy modes used in patients, such as conformal radiotherapy (CRT). Here, we investigated the acute immune infiltration post-CRT. Contrary to non-conformal RT approaches, we found that CRT induces a rapid and robust recruitment of monocytes to the tumor that minimally differentiate into tumor-associated macrophages (TAM) or dendritic cells (DC), but instead upregulate major histocompatibility complex II (MHCII) and costimulatory molecules. We establish that these large numbers of infiltrating monocytes are responsible for increasing type I interferon in the tumor microenvironment (TME), activation of CD8+ T cells and the reduction in tumor burden. Importantly, we demonstrate that rapid monocyte infiltration to the TME is hindered when RT inadvertently affects healthy tissues. Our results unravel a positive role of monocytes during clinically relevant modes of RT and demonstrate that limiting exposure of healthy tissues to radiation has a positive therapeutic effect on the overall immune response within the tumor.
2022-06-30 | MSV000089775 | MassIVE
Project description:Head and neck squamous cell carcinoma (HNSCC) patients have a very short survival. To improve patient survival, there is an emerging need for a better understanding of the obstacles of ionizing irradiation (IR), besides surgery, currently the best treatment option for HNSCC. A confounding factor is the immune suppressive tumor microenvironment (IS-TME) which is orchestrated by tenascin-C (TNC), a highly abundant extracellular matrix (ECM) molecule, getting upregulated by IR. Here, we investigated the roles of TNC on IR-induced tumor regression in a murine oral squamous cell carcinoma (OSCC) model expressing or lacking TNC. While tumors in a TNC-expressing host were radiosensitive, tumors in the TNC genetically-depleted mice were radioresistant pointing at a so far underexplored function of TNC in promoting anti-tumor defense. Upon IR, fibroblast reticular cells (FRCs), a known source of TNC, were more numerous and promoted the IS-TME only in the TNC-expressing tumors. We applied IR to FRCs isolated from lymph nodes and observed that whereas TNC-expressing FRCs were radiosensitive, the TNC-depleted FRCs were radioresistant mimicking the tumor phenotype. Irradiation enhanced the crosstalk of TNC-expressing FRCs with the OSCC causing enhanced tumor cell death but also tumor-promoting plasticity in the survivors as well as induction of Rad51, indicative of enhanced double strand DNA break repair and radioresistance. On the other hand, IR also increased TNC and CCL21 expression in the cocultured FRCs, enforcing an IS-TME. These results demonstrate that TNC determines the FRC tumor promoting phenotype counteracting IR-induced tumor regression, which is relevant in human cancer as a high FRC signature in conjunction with high TNC levels correlates with shorter survival in the irradiated HNSCC patients. We propose that tumor FRCs highly expressing TNC may be an excellent novel target to improve radiotherapy-induced tumor eradication.
2025-02-14 | E-MTAB-14801 | biostudies-arrayexpress
Project description:Tumor endothelial cells (TECs) and corresponding normal endothelial cells (NECs) were isolated from 12 different human colocrectal carcinoma (CRC) patients with different prognostic tumor microenvironments (TME: Th1-TME vs Control-TME).
2023-05-01 | E-MTAB-10465 | biostudies-arrayexpress
Project description:The molecular mechanisms of clinical response or resistance to therapy were evaluated in colorectal cancer patients in a prospective biomarker discovery project. Rectal adenocarcinomas, biopsied before (diagnostic biopsy) and after (surgical resection) pre-operative short-course radiotherapy [RT] or 5-flurouracil (5-FU)-based chemoradiotherapy [CRT], were profiled using Affymetrix HGU133 Plus 2.0 microarrays. Tumour tissues from untreated controls at diagnosis and surgical resection were used to identify treatment-independent gene expression changes. Candidate resistance biomarkers were identified in this pilot study for validation in a larger cohort.
2009-11-10 | E-MEXP-1901 | biostudies-arrayexpress
Project description:Esophageal cancer is one of the common malignant tumors, and the mortality rate ranks fourth among all malignant tumors in China. Radiotherapy is one of the main methods for the treatment of esophageal cancer, and radiation resistance is one of the important factors of tumor recurrence and metastasis. Therefore, the study of radioresistance related markers of esophageal cancer is of great significance to improve the radiosensitivity of esophageal cancer. We used microarrays to detail to find critical prognostic factors for esophageal cancer patients after radiotherapy.
2021-06-16 | GSE137867 | GEO
Project description:The recruitment of monocytes and their differentiation into immunosuppressive cells is associated with the negative outcome of non-conformal radiotherapy (RT). However, non-conformal RT is irrelevant in the clinic, and little is known about the role of monocytes following radiotherapy modes used in patients, such as conformal radiotherapy (CRT). Here, we investigated the acute immune infiltration post-CRT. Contrary to non-conformal RT approaches, we found that CRT induces a rapid and robust recruitment of monocytes to the tumor that minimally differentiate into tumor-associated macrophages (TAM) or dendritic cells (DC), but instead upregulate major histocompatibility complex II (MHCII) and costimulatory molecules. We establish that these large numbers of infiltrating monocytes are responsible for increasing type I interferon in the tumor microenvironment (TME), activation of CD8+ T cells and the reduction in tumor burden. Importantly, we demonstrate that rapid monocyte infiltration to the TME is hindered when RT inadvertently affects healthy tissues. Our results unravel a positive role of monocytes during clinically relevant modes of RT and demonstrate that limiting exposure of healthy tissues to radiation has a positive therapeutic effect on the overall immune response within the tumor. The objective of this experiment was to evaulate the transcriptional changes in monocytes following different modes of radiation at 3 days post treatment
2023-05-07 | GSE223400 | GEO
Project description:Head and neck squamous cell carcinoma (HNSCC) patients have a very short survival. To improve patient survival, there is an emerging need for a better understanding of the obstacles of ionizing irradiation (IR), besides surgery, currently the best treatment option for HNSCC. A confounding factor is the immune suppressive tumor microenvironment (IS-TME) which is orchestrated by tenascin-C (TNC), a highly abundant extracellular matrix (ECM) molecule, getting upregulated by IR. Here, we investigated the roles of TNC on IR-induced tumor regression in a murine oral squamous cell carcinoma (OSCC) model expressing or lacking TNC. While tumors in a TNC-expressing host were radiosensitive, tumors in the TNC genetically-depleted mice were radioresistant pointing at a so far underexplored function of TNC in promoting anti-tumor defense. Upon IR, fibroblast reticular cells (FRCs), a known source of TNC, were more numerous and promoted the IS-TME only in the TNC-expressing tumors. We applied IR to FRCs isolated from lymph nodes and observed that whereas TNC-expressing FRCs were radiosensitive, the TNC-depleted FRCs were radioresistant mimicking the tumor phenotype. Irradiation enhanced the crosstalk of TNC-expressing FRCs with the OSCC causing enhanced tumor cell death but also tumor-promoting plasticity in the survivors as well as induction of Rad51, indicative of enhanced double strand DNA break repair and radioresistance. On the other hand, IR also increased TNC and CCL21 expression in the cocultured FRCs, enforcing an IS-TME. These results demonstrate that TNC determines the FRC tumor promoting phenotype counteracting IR-induced tumor regression, which is relevant in human cancer as a high FRC signature in conjunction with high TNC levels correlates with shorter survival in the irradiated HNSCC patients. We propose that tumor FRCs highly expressing TNC may be an excellent novel target to improve radiotherapy-induced tumor eradication.
2026-01-14 | PXD060164 | Pride
Project description:Radiotherapy (RT) primes the immune system against cancer antigens but fails to trigger effective antitumor responses due to concomitant induction of immunosuppressive factors. To expand the benefits of RT, we combine local radiation with immuno-gene therapy by harnessing the ability of ionizing radiation to enhance AAV-mediated tumor transduction. To successfully deliver AAV-based local immunotherapy and restrict transgene expression within tumors, we designed a recombinant AAV that expresses IL-12 through an interferon (IFN)-inducible promoter (AAV-iIL12). Local administration of AAV-iIL12 upon RT results in marked and durable elevation of intratumor IL-12 with minor and transient systemic release. This strategy generates a highly immunostimulatory tumor microenvironment (TME) leading to strong antitumor responses in an IFNg-dependent manner. Moreover, local treatment with RT and AAV-iIL12 elicits systemic antitumor immunity with marked CD8+ T cell infiltration and regression of distant tumors. Our work shows that radiation coupled with AAV-based immuno-gene delivery is a novel, efficient and safe approach that can be exploited as cancer therapy.
2026-02-06 | GSE280079 | GEO